Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
about
Current and future directions for treating hepatitis B virus infectionTenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.Single-Tablet Regimens in HIV TherapyPharmacogenomics of antimicrobial agents.Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Search for a cure for chronic hepatitis B infection: How close are we?In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Investigational reverse transcriptase inhibitors for the treatment of HIV.Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Tenofovir and bone health.A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure ProphylaxisPharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal ImpairmentTenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.Emerging antiretroviral drugs.Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.Darunavir/cobicistat once daily for the treatment of HIV.The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.Hepatitis B: Working Towards a Cure.New paradigms in hepatitis B management: only diamonds are forever.Proteins, peptides, polysaccharides, and nucleotides with inhibitory activity on human immunodeficiency virus and its enzymes.Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.The role of tenofovir alafenamide in future HIV management.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Bone Loss in HIV Infection.Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Renal effects of novel antiretroviral drugs.Tenofovir Alafenamide.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Single-Tablet Regimens for the Treatment of HIV-1 Infection.Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
P2860
Q26851240-FEC6887B-C876-49F7-9238-36902B6E6C34Q30843736-996E0074-F854-4869-854B-1E58DAB5526FQ33460754-34EEA041-2411-4096-A1F9-42746C88298EQ33939110-7086BC15-E979-41CD-901C-9446CC364F25Q34977413-93BABA5E-990E-463D-993A-0FF2D56CF525Q35171168-89BC2AF9-C42D-4E06-B9DB-A3A666321FC9Q35567828-A0585E7C-19AE-4EC5-BE67-CB2EE14386D2Q35626790-EA711ACD-6623-48B5-84E1-9F5BBCF76158Q36075908-67ADC456-1B01-4AAC-9CB7-9014D733E955Q36076011-7A5EBB22-813C-4E38-AA59-5DAA0489AAD9Q36219963-6DCD9776-2805-43A9-BD6D-7363225AB06AQ36275141-D1B64325-BF5F-49FB-92E3-26E52D1D38CCQ36306231-D23B4648-C207-4A3F-B220-A273784700CDQ36663586-BC8609CB-3C11-4C75-A42A-712F0E3EC2BEQ36833961-D27ED9F5-EEF3-4793-84F4-314EECE35C73Q36968405-5648D9D2-9449-4F6A-ABF0-B5CACBCC19B1Q37203743-066B5ABE-2309-470C-B7D2-B77EB4CAC971Q37242504-90AAC889-3874-4BEB-BC60-29DB71BC4302Q37693640-CF493E09-048F-452C-9FF6-A042EDA28893Q38167382-15801808-64C3-42C4-B4AB-A435CD1D40D5Q38447283-C2FCB878-3578-4751-88F7-523E525A154EQ38472696-AEF487EC-AEBD-49CE-911F-06D966A33A46Q38520954-745E1E6D-0299-486E-8E82-1AAACB86D3C1Q38566984-B9A5328C-12F2-4C75-AB18-149F73F6B752Q38588187-50861782-09AA-4C2A-AAE3-C3A4CD4DAE6BQ38593985-94CDA734-A342-4ED0-80F2-70BFAC164BF7Q38609568-9C0CA361-66B5-441D-9C12-ACFA8E032B4CQ38661064-9E4AA867-53EA-436B-B09D-755981142BEAQ38764695-2E3A6628-79DD-4F31-9125-4E293E64B243Q38802093-6E592236-8A9D-466F-AAC2-E45373856844Q38835028-A69724CE-2F66-4A50-B37A-0342E887B0F3Q38836878-76B2D977-1D33-4A13-B618-5E6F4CAE84FDQ38837077-FD543B1D-B455-4D4B-86B5-0CAAAB6FE75AQ38910661-8010228E-0DC0-47F6-8BCC-06F6F486ED7BQ38984695-F7ED9FD5-4AB6-4802-B217-C1B20DE3FA98Q38997526-602FE4FB-5B8E-4CB2-9724-808045ED2BB5Q39002230-87E77A20-488B-40CA-A758-9CF0C9CA9F5AQ39022885-255B610B-9C99-4F32-A4DE-96885E09751CQ39275759-28D7F011-3523-4087-8822-DFDBC295B534Q40185119-C1A174DE-32C8-4AEC-BCB3-D7202B1F9639
P2860
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antiviral activity, safety, an ...... rapy in HIV-1-positive adults.
@en
Antiviral activity, safety, an ...... rapy in HIV-1-positive adults.
@nl
type
label
Antiviral activity, safety, an ...... rapy in HIV-1-positive adults.
@en
Antiviral activity, safety, an ...... rapy in HIV-1-positive adults.
@nl
prefLabel
Antiviral activity, safety, an ...... rapy in HIV-1-positive adults.
@en
Antiviral activity, safety, an ...... rapy in HIV-1-positive adults.
@nl
P2093
P1476
Antiviral activity, safety, an ...... rapy in HIV-1-positive adults.
@en
P2093
Christian Callebaut
Daniel Berger
Edwin DeJesus
Kitty Yale
Lijie Zhong
Marshall W Fordyce
Martin Markowitz
Martin S Rhee
Peter J Ruane
Srini Ramanathan
P304
P356
10.1097/QAI.0B013E3182965D45
P407
P577
2013-08-01T00:00:00Z